戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 fficiently in the presence of the CD70-fiber bispecific antibody.
2 ed in the same cell to assemble a functional bispecific antibody.
3    Using this approach, we produce 28 unique bispecific antibodies.
4 d in the same cell to generate heterodimeric bispecific antibodies.
5 ction provides a novel synthetic approach to bispecific antibodies.
6  small-scale generation of human full-length bispecific antibodies.
7 armacophores to generate optimized or unique bispecific antibodies.
8 ltaneous targeting of two tumor targets with bispecific antibodies.
9  and improved sources of clinically relevant bispecific antibodies.
10 ery with possible functional implications in bispecific antibodies.
11 tent antibodies and explore the potential of bispecific antibodies.
12                                          One bispecific antibody, 10E8V2.0/iMab, neutralized 118 HIV-
13                                We produced a bispecific antibody (3F12) which binds influenza virus M
14          With the recent clinical success of bispecific antibodies, a strategy to rapidly synthesize
15 nd, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable re
16 NA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab.
17                                  Synergistic bispecific antibodies against HIV exhibit extraordinary
18                           We have shown that bispecific antibodies against TfR and beta-secretase (BA
19                                  We report a bispecific antibody against B cell maturation antigen (B
20                                            A bispecific antibody against the receptor tyrosine kinase
21   Here, we describe the synthesis of a novel bispecific antibody, alphaCLL1-alphaCD3, using the genet
22 mune activation of cytotoxic effector cells, bispecific antibodies and antibodies linked to superanti
23                                              Bispecific antibodies and antibody fragments are a new c
24 rogeneous biopharmaceutical products such as bispecific antibodies and antibody mixtures.
25 ntibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell therapy.
26   These results support this new approach to bispecific antibodies and offer a potential new strategy
27 successfully redirected to tumor cells using bispecific antibodies and offer a promising strategy for
28                                              Bispecific antibodies and recombinant proteins are also
29 rved following administration of natural and bispecific antibodies and, more recently, following adop
30 ased on a glycoprotein A33 (GPA33)-targeting bispecific antibody and a small-molecule radioactive hap
31                                              Bispecific antibody and antibody-like molecules are of w
32 Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902.
33  undergo in vivo Fab arm exchange leading to bispecific antibody and off-target effects.
34 Fc containing therapeutics (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of
35 , leading to the formation of monovalent but bispecific antibodies, and it interacts poorly with Fcga
36 position of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate
37 ess in research on intracellular antibodies, bispecific antibodies, antibody-fusion molecules, and an
38 otein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles tha
39                                              Bispecific antibodies are considered attractive bio-ther
40 the generation of large numbers of different bispecific antibodies are presented.
41         These results suggest that IgG-based bispecific antibodies are promising candidates for the p
42                       However, FVIII and the bispecific antibody are fundamentally different proteins
43                 Chimeric proteins, including bispecific antibodies, are biological tools with therape
44 ignaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of
45                           The development of bispecific antibodies as therapeutic agents for human di
46  payloads such as other antibodies to create bispecific antibodies as well as organic and non-organic
47 nity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 dis
48              Comparison with a single-chain, bispecific antibody bearing identical CD19 and CD3 antib
49                        Chemically programmed bispecific antibodies (biAbs) endow target cell-binding
50                                              Bispecific antibodies (biAbs) that mediate cytotoxicity
51 o 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogou
52 this approach to the development of chimeric bispecific antibody binding site (chi BABS) proteins.
53 e used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive
54 pecificities can dissociate and recombine in bispecific antibodies both in vitro and in vivo.
55 ltaneous engagement of two distinct targets, bispecific antibodies broaden the potential utility of a
56    We previously described a highly flexible bispecific antibody (bs-mAb) pretargeting procedure usin
57 ied using PrA-MS and are presented here: (a) bispecific antibodies (bsAb) and (b) glycan engineered a
58     Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives ar
59 nical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially signif
60                                   The use of bispecific antibodies (BsAb) provides integration of the
61                            T cell-recruiting bispecific antibodies (bsAb) show promise in hematologic
62 ted and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and I
63 ectively targeted against malignant B cells, bispecific antibodies (BsAb) were constructed from two a
64 s such as antibody-drug conjugates (ADC) and bispecific antibodies (bsAb), are the fastest growing cl
65 d DNL to generate a novel class of trivalent bispecific antibodies (bsAb), each comprising an anti-CD
66 for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).
67 ived macrophages mediated by MAb DF3 and its bispecific antibody (BsAb) DF3xH22 with the second epito
68      In order to target alpha v integrins, a bispecific antibody (bsAb) that comprised a monoclonal A
69 inical evaluation of a recombinant AC133xCD3 bispecific antibody (bsAb) that redirects human polyclon
70                    Among these, a Her2 x CD3 bispecific antibody (BsAb) was constructed by inserting
71  These deficiencies were overcome by using a bispecific antibody (bsAb) with specificities for human
72                                              Bispecific antibodies (bsAbs) and antibody-drug conjugat
73                                              Bispecific antibodies (bsAbs) are Abs composed of two di
74                                              Bispecific antibodies (bsAbs) are of significant importa
75                                              Bispecific antibodies (bsAbs) are one of the most versat
76                                              Bispecific antibodies (BsAbs) are regarded as promising
77                                              Bispecific antibodies (bsAbs) combine the antigen specif
78  a pair of humanized hexavalent anti-CD20/22 bispecific antibodies (bsAbs) derived from veltuzumab (v
79                                  We prepared bispecific antibodies (bsAbs) for disease-specific targe
80  Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial application
81 cacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relativ
82 g T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy.
83              Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for precl
84                                              Bispecific antibodies (BsAbs) target multiple epitopes o
85                                              Bispecific antibodies (bsAbs) that lack the immunoglobul
86                               The promise of bispecific antibodies (bsAbs) to yield more effective th
87                    Four different formats of bispecific antibodies (bsAbs) were generated that consis
88 onal mouse anti-TnI IgG mAb 265, (2) TnI and bispecific antibodies (BsAbs) which on one end recognize
89     This results in functionally monovalent, bispecific antibodies (bsAbs) with unknown specificity a
90                                              Bispecific antibodies (bscAbs), particularly those of th
91  chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with (1
92 ing method using a new recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-1,4,7,10-t
93                                   A flexible bispecific antibody (bsMAb) multistep, pretargeting syst
94                                              Bispecific antibodies, but not parent mAbs, neutralized
95                       We have produced novel bispecific antibodies by fusing the DNA encoding a singl
96 rm of generating bispecific IgG antibodies, "Bispecific Antibody by Protein Trans-splicing (BAPTS)".
97 e, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cel
98                            We show that IgG4 bispecific antibodies can be generated in large quantiti
99                                              Bispecific antibodies can be used to redirect cytotoxic
100 us, Ad) vectors targeted to CD40 by means of bispecific antibodies can enhance gene transfer to murin
101   These results indicate that the CD70-fiber bispecific antibody can enhance rAd infection of CD70-po
102 he two parental antibodies and that a single bispecific antibody can neutralize 97% of viral strains
103                                              Bispecific antibodies capable of redirecting the lytic p
104                                              Bispecific antibodies combine two different antigen-bind
105 egies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, a
106 act specifically with the capture arm of the bispecific antibody complex were used to demonstrate the
107                                       Use of bispecific antibody complexes and (99m)Tc-DTPA-succinyl-
108                                              Bispecific antibody complexes and (99m)Tc-labeled negati
109 vel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (V
110 nsfer specifically to tumor cells, we used a bispecific antibody conjugate to ablate Ad binding to fi
111                            Here we show that bispecific antibodies contain the binding specificities
112 n leukemic cytotoxic T cells triggered via a bispecific antibody containing an anti-CD3 F(ab') to kil
113 l trials have been initiated to test whether bispecific antibodies could redirect immune effectors ag
114 dentical for native diphtheria toxin and the bispecific antibody. CRM107 combination.
115                                     However, bispecific-antibody design and production remain challen
116 d a DropArray cell-based assay to evaluate a bispecific antibody designed to engage cytotoxic T cells
117 sozyme-specific antibody fragments, creating bispecific antibodies (diabodies).
118                                              Bispecific antibodies directed against transferrin recep
119        Catumaxomab (CatmAb), a trifunctional bispecific antibody directed against the epithelial cell
120 nded the technology by developing a two-part bispecific antibody discovery strategy that facilitates
121                             In contrast, the bispecific antibody does not enhance Ad-GFP infection in
122                                         This bispecific antibody efficiently induces targeted cell ly
123                                        All 3 bispecific antibodies exhibited identical pharmacokineti
124 er T (NKT) cells retargeted with a humanized bispecific antibody F(ab')(2)HER2xCD3.
125 tional monoclonal antibodies, knob-into-hole bispecific antibodies face unique challenges in producti
126  experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR
127      To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a seco
128 ath to generating highly effector-attenuated bispecific antibodies for preclinical studies.
129            These findings support the use of bispecific antibodies for the prevention or treatment of
130 h the identification of a common light chain bispecific antibody for large-scale production with high
131 adionuclides, a new anti-Trop-2 x antihapten bispecific antibody for pretargeting, based on humanized
132     While the clinical potential for certain bispecific antibody formats is clear, progress has been
133 en hindered by the difficulty of identifying bispecific antibody formats that exhibit favorable pharm
134                     We describe the use of a bispecific antibody fragment (diabody) to recruit the wh
135                 The therapeutic potential of bispecific antibody fragments and Fc-containing proteins
136  the construction of other disease-targeting bispecific antibody fragments for early detection and di
137 provides a versatile platform for generating bispecific antibody fragments for redirected killing and
138      Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies a
139 increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nan
140                     Robust generation of IgG bispecific antibodies has been a long-standing challenge
141                          Although human IgG1 bispecific antibodies have been generated, few attempts
142                                              Bispecific antibodies have been used in different cell s
143                                        Human bispecific antibodies have great potential for the treat
144                                              Bispecific antibodies have great potential to be the nex
145 orm conventional monoclonal antibodies, many bispecific antibodies have issues regarding production,
146                    Many different formats of bispecific antibodies have meanwhile been developed.
147                          Such "Trojan horse" bispecific antibodies have potential as broad antifilovi
148 nerality of the approach and show that these bispecific antibodies have properties similar to those o
149                                              Bispecific antibodies have therapeutic potential by expa
150 eting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therape
151                                              Bispecific antibodies having binding specificities for t
152  this study, we describe a trastuzumab-based bispecific antibody, HER2-TDB, which targets HER2 and co
153 ti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)), follow
154                                        These bispecific antibodies hold promise as novel prophylactic
155 i-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconj
156  scaffolds offers the possibility to produce bispecific antibodies in vitro.
157         Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affini
158              In this study, we characterized bispecific antibodies in which a BBB-crossing antibody f
159                           The engineering of bispecific antibodies in which a therapeutic "arm" is co
160 g, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is preci
161                                              Bispecific antibodies, including bispecific IgG, show so
162                   We demonstrate here that a bispecific antibody incorporating a broadly reactive ant
163 in advance of the radiolabeled veltuzumab or bispecific antibody injection, tumor uptake was signific
164 T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the tr
165                   This unique antiangiogenic bispecific antibody is in phase-1 clinical trials.
166                                              Bispecific antibody is synthesized by covalently linking
167 s of the efficient small-scale generation of bispecific antibodies lacking a common light chain and t
168 , semisynthetic method for the production of bispecific antibody-like therapeutics in which a derivat
169      Using the DEKK format, we generated the bispecific antibody MCLA-128, targeting human EGF recept
170                                            A bispecific antibody, MDX-H210, was developed to target c
171 totoxic potential, however, was restored via bispecific antibody-mediated delivery and release within
172                                        Using bispecific antibodies of different valencies to cell sur
173                                     Emerging bispecific antibodies offer the potential for even bette
174 corporation of FC5 as the BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers
175 ernative using either (strept)avidin/biotin, bispecific antibodies, or oligomers.
176      We describe the application of a novel, bispecific antibody platform termed dual affinity retarg
177                              A BCMA-targeted bispecific antibody presents a promising treatment optio
178 e dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficien
179                                              Bispecific antibody pretargeting has a significant advan
180                                              Bispecific antibody pretargeting is highly sensitive and
181                                              Bispecific antibody pretargeting is highly specific for
182 s applied to a peptide suitable for use in a bispecific antibody pretargeting method.
183 ability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to gene
184                            Here we present a bispecific-antibody production strategy that relies on c
185 R suggest avenues for the development of new bispecific antibody-promoted treatment strategies.
186                              Emicizumab is a bispecific antibody recognizing both the enzyme factor I
187                                              Bispecific antibodies represent one such strategy in whi
188                              This innovative bispecific antibody scaffold that simultaneously engages
189 an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery
190                                              Bispecific antibodies show great promise as intrinsic co
191 ing distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity
192 ites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER
193                          Here, we describe a bispecific-antibody strategy to target this interaction,
194 s and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of dis
195 e have applied this technology to generate a bispecific antibody suitable for development as a human
196          The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage mar
197 port our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype
198 state cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-
199                 The anti-Trop-2 x antihapten bispecific antibody, TF12, was prepared using the modula
200 onic tumors pretargeted with an anti-CEACAM5 bispecific antibody (TF2).
201                   Here, we report engineered bispecific antibodies that are the most potent and broad
202  gammadelta T-cell cytotoxicity, we designed bispecific antibodies that bind CD3 or Vgamma9 on gammad
203 g sites, such as epratuzumab and HU1D10, and bispecific antibodies that can directly interact with ce
204 latform for the mammalian cell production of bispecific antibodies that differ from their parental mA
205 odies that utilize a common light chain, and bispecific antibodies that pair light chains to their co
206      With this approach, we generated potent bispecific antibodies that recruit cytotoxic T lymphocyt
207                                    Recently, bispecific antibodies that redirect the cytotoxic activi
208         Taken together, our results show how bispecific antibodies that selectively recruit gammadelt
209 antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain,
210               As a prototype, we developed a bispecific antibody that binds both vascular endothelial
211 eloid-Specific TNF Inhibitor)--a recombinant bispecific antibody that binds to the F4/80 surface mole
212 the technology with an example of a CD3/CD20 bispecific antibody that effectively depletes B cells in
213                                            A bispecific antibody that has two different antibody bind
214 rmined whether therapeutic responses using a bispecific antibody that pretargeted (90)Y-hapten-peptid
215         We apply this approach to generate a bispecific antibody that targets IL-4 and IL-13, two cyt
216                                          For bispecific antibodies, the ratio of the expression level
217 tibodies enables the clinical application of bispecific antibodies to a validated therapeutic pathway
218 ted in the scientific literature that extend bispecific antibodies to other human antibody isotypes.
219                               The ability of bispecific antibodies to simultaneously bind two unique
220 racer in situ by pretargeting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), w
221                        Here, we engineered a bispecific antibody to detect K11/K48-linked chains and
222 domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker
223 Abs with the potency of cytotoxic agents via bispecific antibody-toxin conjugation.
224 e, we describe a new approach for generating bispecific antibodies using a common light chain format
225             The dual binding capacity of the bispecific antibodies was confirmed by delivery of 125I-
226                       As proof-of-concept, a bispecific antibody was employed as an adaptor that phys
227 ons triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted
228                         Using the CD70-fiber bispecific antibody, we increased the ability of rAd vec
229                                              Bispecific antibodies were constructed using genetically
230                                              Bispecific antibodies were designed to deliver a reversi
231                   Approximately 40 microg of bispecific antibodies were injected intravenously after
232 sing T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cel
233 apid generation and chemical optimization of bispecific antibodies, which are termed bispecific CovX-
234                                              Bispecific antibodies, which simultaneously target CD3 o
235 ology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inh
236 proach, we synthesized an anti-HER2/anti-CD3 bispecific antibody, which efficiently cross-linked HER2
237 des additional options for the generation of bispecific antibodies with differing effector functions
238 t of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the t
239  broadens the range of published therapeutic bispecific antibodies with natural surface architecture
240 e efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties ver
241                                  Labeling of bispecific antibodies with single-photon-emitting isotop
242 itions, resulting in a formation of a stable bispecific antibody with high yields.
243 ases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations i
244          We therefore investigated whether a bispecific antibody with specificities for the adenoviru
245 ultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor act
246                                          The bispecific antibody XGFR is based on the "knob-into-hole
247 owever, most approaches utilized to generate bispecific antibodies yield antibody-like structures tha

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top